Randomised trials in ovarian cancer: trial design considerations

被引:6
作者
Brady, MF
Thigpen, JT
Vermorken, JB
Parmar, MKB
机构
[1] Roswell Pk Canc Inst, GOG Stat Off, Buffalo, NY 14263 USA
[2] Univ Mississippi, Sch Med, Dept Med, Jackson, MS 39216 USA
[3] Univ Antwerp Hosp, Dept Med Oncol, Edegem, Belgium
[4] MRC, Canc Trials Off, Cambridge, England
关键词
end point selection; progression-free survival; response; survival; trial size;
D O I
10.1023/A:1008319704310
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Randomised clinical trials are considered the definitive source of evidence for guiding decisions in clinical practice. The concept of a clinical trial is based on sound scientific, ethical, and practical principles. The strength of evidence that an individual trial provides is assessed on the manner in which these principles are incorporated into the design and execution of the trial. Since the way these principles are incorporated into a trial is judgmental, the strength of evidence from an individual trial is a matter of degree. The purpose of this paper is to present some of the scientific, ethical and practical considerations surrounding the selection of endpoints and determination of sample size for trials in ovarian cancer.
引用
收藏
页码:75 / 82
页数:8
相关论文
共 30 条
[1]   LOSS OF POWER FROM AN OPTIMISTIC ALTERNATIVE HYPOTHESIS [J].
BLUMENSON, LE .
STATISTICS IN MEDICINE, 1988, 7 (04) :457-466
[2]   SAMPLE SIZES FOR CONSTRUCTING CONFIDENCE-INTERVALS AND TESTING HYPOTHESES [J].
BRISTOL, DR .
STATISTICS IN MEDICINE, 1989, 8 (07) :803-811
[3]   2ND-LOOK LAPAROTOMY IN OVARIAN-CANCER [J].
CREASMAN, WT .
GYNECOLOGIC ONCOLOGY, 1994, 55 (03) :S122-S127
[4]   SELECTION BIAS IN OBSERVATIONAL AND EXPERIMENTAL STUDIES [J].
ELLENBERG, JH .
STATISTICS IN MEDICINE, 1994, 13 (5-7) :557-567
[5]   SAMPLE-SIZE - HOW MANY PATIENTS ARE NECESSARY [J].
FAYERS, PM ;
MACHIN, D .
BRITISH JOURNAL OF CANCER, 1995, 72 (01) :1-9
[6]  
Fayers PM, 1997, STAT MED, V16, P1413, DOI 10.1002/(SICI)1097-0258(19970630)16:12<1413::AID-SIM578>3.0.CO
[7]  
2-U
[8]   Surrogate end points in clinical trials: Are we being misled? [J].
Fleming, TR ;
DeMets, DL .
ANNALS OF INTERNAL MEDICINE, 1996, 125 (07) :605-613
[9]   IMPORTANCE OF BETA, TYPE-II ERROR AND SAMPLE-SIZE IN DESIGN AND INTERPRETATION OF RANDOMIZED CONTROL TRIAL - SURVEY OF 71 NEGATIVE TRIALS [J].
FREIMAN, JA ;
CHALMERS, TC ;
SMITH, H ;
KUEBLER, RR .
NEW ENGLAND JOURNAL OF MEDICINE, 1978, 299 (13) :690-694
[10]   INTERIM ANALYSES IN RANDOMIZED CLINICAL-TRIALS - RAMIFICATIONS AND GUIDELINES FOR PRACTITIONERS [J].
GELLER, NL ;
POCOCK, SJ .
BIOMETRICS, 1987, 43 (01) :213-223